APOB and metabolic syndrome: These results are of particular importance for patients with diabetes, obesity, metabolic syndrome, and hypertriglyceridemia, for whom the latest guidelines have defined secondary goals for non-HDL-C and apoB levels for more accurate risk assessments, even after the recommended LDL-C goal is attained [13].